The outcomes from this study revealed that Plexozome® curcumin at a concentration corresponding to 2.5 μM curcumin significantly downregulates the CSE-induced expression of IL-8 and IL-24 in BCi-NS1.1 human bronchial cells, showcasing the potential of this formulation as an effective therapy for COPD. The gene discussed is CXCL8; the disease is chronic obstructive pulmonary disease.